Genesys Capital | Genesys University Seed Fund

vc$300MCo-investsLeads rounds

◆ Fund Size

$300M

◆ Check Size

$9.3M→$105.0M

◆ Location

Canada

◆ Portfolio

7 companies

◆ Activity

Statusactively investing

◆ Links

Website ↗@genesyscapital on X ↗

◆ Investment Thesis

Early-stage capital for university-affiliated life sciences startups to translate research into viable companies addressing critical health challenges.

◆ About Genesys Capital

Genesys Capital is one of Canada's leading venture capital firms, dedicated to investing in early-stage healthcare and biotechnology companies. With over 25 years of experience, the firm has a proven track record of identifying and nurturing innovative bioscience opportunities, transforming them into commercially successful enterprises.

◆ Sectors

BiotechDrug DiscoveryDiagnosticsMedtechDigital Health

◆ Stages

pre-seedseed

◆ Geography Focus

CanadaOntario

◆ Team

Name	Title	Role	Links
Christine Thoburn	Office Manager	Office Manager	in
Damian Lamb	Co-founder, Managing Director	Managing Director	in
Jamie Stiff	Managing Director	Managing Director	in
Jennifer Williams	Partner and Chief Financial Officer	Partner	in
Kelly Holman	Co-founder, Managing Director	Managing Director	in
Laurie Mak	Associate	Associate
Lisa Low	Senior Vice President, Finance	Senior Vice President	in
Sarah Farr	Principal	Principal	in

◆ Notable Investments

Feldan TherapeuticsAfyniaFlosonics MedicalInversago PharmaWicked TechnologiesFusion Pharmaceuticals (acquired by AstraZeneca for USD $2.4 billion, June 2024)Inversago (acquired by Novo Nordisk for USD $1.1 billion, September 2023)Naurex (acquired by Allergan for USD $1.7 billion, August 2015)Epocal (acquired by Alere/Abbott Labs for USD $225 million, February 2013)Affinium (acquired by Debiopharm for USD $127 million, February 2014)Invitae (divested NYSE:NVTA, 2019-2020)Aptinyx (IPO NASD:APTX, 2018-2019)IDbyDNA (acquired by Illumina for USD $90 million, June 2022)Ionalytics (acquired by Thermo Electron Corporation for USD $35 million, August 2005)XLTEK (acquired by Natus Medical for USD $44 million, November 2007)Delex (acquired by YM Biosciences/Gilead, May 2005)Millennium (acquired by Medtronic, April 2007)Fairhaven Pharmaceuticals (acquired by Liminal Biotherapeutics, July 2020)SXC (divested TSX:SXC, 2003)Xillix (divested TSX:XLX, 2004-2005)

◆ Traits

Leads rounds

Co-invests

◆ FAQ

What does Genesys University Seed Fund invest in?

Genesys University Seed Fund invests in Biotech, Drug Discovery, Diagnostics, Medtech and Digital Health at the pre-seed and seed stages.

Which geographies does Genesys University Seed Fund focus on?

Genesys University Seed Fund focuses on Canada and Ontario, and is headquartered in Canada.

What is Genesys University Seed Fund's typical check size?

Genesys University Seed Fund typically writes checks of $9.3M to $105M.